

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Histamine H3 receptor (HRH3); norepinephrine transporter	<p><i>In vitro</i> and rat studies identified a dual inhibitor of HRH3 and norepinephrine transporter that could help treat osteoarthritic pain. <i>In vitro</i>, the biphenylmethyl analog inhibited HRH3 with a K_i value of 37 nM and the norepinephrine transporter with a K_i value of 14 nM. In a rat model of osteoarthritic pain, the lead compound decreased pain compared with vehicle. Next steps could include evaluating the compound in additional animal models of pain.</p> <p>At least six companies have compounds that inhibit the norepinephrine transporter in Phase II trials or earlier to treat pain.</p> <p>SciBX 3(43); doi:10.1038/scibx.2010.1299 Published online Nov. 4, 2010</p>	Patent and licensing status unavailable	Altenbach, R.J. <i>et al. J. Med. Chem.</i> ; published online Oct. 14, 2010; doi:10.1021/jm100666w Contact: Robert J. Altenbach, Abbott Laboratories, Abbott Park, Ill. e-mail: robert.j.altenbach@abbott.com